Key Points {#FPar1}
==========

In the first week after thoracic organ transplantation, the inter-occasion (dose-to-dose) variability of pharmacokinetic parameters were shown to be far higher than the interindividual variability (IIV), and were found to be mainly due to excessive variability in bioavailability.Such huge variabilities hamper any attempt to predict the appropriate tacrolimus concentration for the next dose based upon previous concentrations measured during the first days post-transplantation.Theoretically, tacrolimus therapy may be optimised in clinically unstable patients by circumventing the bioavailability issue through the use of intravenous administration.

Introduction {#Sec1}
============

The immunosuppressant tacrolimus, which is a calcineurin inhibitor, is used extensively in thoracic organ transplantation patients. Tacrolimus is generally administered orally because of the suspected hepatotoxicity and nephrotoxicity of the solvent polyoxyl 60 hydrogenated castor oil (HCO-60) used in intravenous formulations \[[@CR1], [@CR2]\]. Unfortunately, tacrolimus has a narrow therapeutic range, making it difficult to attain therapeutic targets in clinically unstable patients, such as patients early after heart and lung transplantation \[[@CR3], [@CR4]\]. Yet, adequate therapeutic exposure is very important, because a variable tacrolimus concentration increases the risk of transplanted organ dysfunction and death \[[@CR5]--[@CR7]\]. A supratherapeutic whole-blood tacrolimus trough concentration in the first week after thoracic transplantation has been related to acute kidney injury (AKI), which is, on its own, a risk factor for poor outcome \[[@CR3], [@CR4], [@CR8]--[@CR10]\]. Therefore, pharmacokinetic-guided dosing is of vital importance and is now commonplace. The most important prerequisite for appropriate dosing based on measured drug concentrations is that exposure after dose adaptation can be adequately predicted based on the measured exposure after previous doses. This requires that the dose-to-dose variability is relatively low compared to the interindividual variability (IIV). As a consequence, knowledge of the complex pharmacokinetics of tacrolimus in clinically unstable thoracic organ recipients is crucial. However, only a few studies on the pharmacokinetics of oral tacrolimus early after thoracic organ transplantation have been performed. Those studies showed that the pharmacokinetics varied with the patient group considered; for instance, a 40% lower bioavailability was observed in cystic fibrosis (CF) patients, and a 40% higher clearance in cytochrome P450 3A5 (CYP3A5) expressers \[[@CR11]--[@CR17]\]. Also, a low clearance rate has been observed in heart transplant recipients early post-transplantation \[[@CR18]\]. The inter-occasion (dose-to-dose) variability (IOV) of oral tacrolimus pharmacokinetics early post-transplantation was studied by Miano et al. Their study showed that CYP3A5 combined with CYP3A4\*22 expression along with clinical factors such as the use of CYP450 inhibitors (azole antifungals, amiodarone), the transplant type, a diagnosis of cystic fibrosis and haematocrit accounted for 42% of the variance in the dose-corrected concentration during the first 2 weeks after lung transplantation \[[@CR19]\]. Organ dysfunction (such as gut dysmotility and liver dysfunction) and the use of extended extracorporeal life support were not taken into account. Thoracic organ recipients often experience prolonged surgery times, ischaemia of the transplanted organ(s), reperfusion oedema, acute rejection, bleeding and massive blood transfusions or infection, which result in shock, inflammation and organ failure \[[@CR20], [@CR21]\]. Due to all of the abovementioned changes, altered drug bioavailability, distribution, metabolism and clearance will influence the pharmacokinetics of tacrolimus early after thoracic organ transplantation.

We hypothesised that thoracic organ recipients show high variability in 12-h post-dose whole-blood concentrations of tacrolimus (C12 h) during the first days after transplantation. We analysed oral tacrolimus pharmacokinetics in 10 heart and 20 lung transplants within the first 6 days after transplantation.

Patients and Methods {#Sec2}
====================

Compliance with Ethical Standards {#Sec3}
---------------------------------

This was a descriptive and prospective study in 10 heart and 20 lung transplantation patients in the first 6 days after transplantation. Informed consent was obtained from all individual participants included in the study. The accredited review board for human studies of the University Medical Center Utrecht (UMC Utrecht) approved the study (NTR 3912/EudraCT 2012-001909-24).

Patients {#Sec4}
--------

All consecutive thoracic organ recipients who were admitted to the intensive care unit (ICU) of the UMC Utrecht between June 2013 and March 2015 and met the inclusion criteria but not the exclusion criteria were studied. The inclusion criteria were patients older than 18 years who were treated with tacrolimus and provided informed consent. Exclusion criteria were patients who died within 1 day after admission, had known allergies to tacrolimus and macrolides, or received total parenteral nutrition.

The Immunosuppressive Regimen {#Sec5}
-----------------------------

Tacrolimus (Prograf^®^, Astellas Pharma Europe) was dosed orally twice daily (bid). The initial dose was 0.1 mg/kg bid for the lung transplantation patients and 2 mg bid for the heart transplantation patients, and was started the day after transplantation. Dose adjustments were based on whole-blood tacrolimus concentrations 12 h post-dose (C12 h) taking drug--drug interactions, gut dysmotility and liver injury into account, and were left at the discretion of the attending physicians. The therapeutic range was from 9 to 15 ng/ml for all patients \[[@CR22]\]. Steady state had not necessarily been reached when dose adjustments were made, in accordance with common clinical practice.

The immunosuppressive regimen of heart recipients further consisted of corticosteroids \[prednisolone 50 mg intravenously directly postoperative, followed by 25 mg bid\] and mycophenolate mofetil (MMF) \[1000 mg orally bid\]. For lung transplantation recipients, the immunosuppressive regimen consisted of basiliximab induction therapy on postoperative days 1 and 4 \[20 mg per day intravenously\], corticosteroids \[prednisolone 25 mg four times per day (qid) intravenously, tapered to 30 mg once daily orally after 4 days\] and MMF \[starting dose 1500 mg orally bid, tapered to 1000 mg bid\].

Tacrolimus Analyses {#Sec6}
-------------------

Twelve-hour whole-blood tacrolimus concentrations were determined daily from the transplantation date until 6 days after transplantation as long as the patients were admitted to the intensive care. Blood samples were collected daily during one dose interval \[sampled pre-dose and at 1, 1 ½, 2, 2 ½, 3, 4, 6, 8, and 12 h after administration\]. The stability of tacrolimus was tested for up to 1 week at room temperature. There was no decline in the tacrolimus concentration in whole-blood samples. All whole-blood samples were analysed within 24 h. Analysis of tacrolimus was performed using high-performance liquid chromatography tandem mass spectrometry (HPLC--MS/MS) (Thermo Fisher Scientific), with a lower limit of quantification of 0.5 ng/ml and an intraday imprecision of \< 5%. The HPLC--MS/MS method was adapted from and validated according to the latest European Medicines Agency (EMA) guidelines \[[@CR23]\]. The on-column stability was 24 h and the assay runtime was a maximum of 8 h. Assay specificity was 100% due to the use of HPLC--MS/MS. Cross-reactivity with drugs commonly used in thoracic organ transplant recipients was tested for, and no interference was detected. The assay had a linear dynamic range of 1--50 ng/ml. The between-run and between-day imprecisions (as measured by coefficients of variation) were within 10%, and the bias was under 3%. Low, median and high controls were all within 15%. Furthermore, 5 years of results from an international interlaboratory proficiency testing program for tacrolimus showed that measurements for all external quality controls were within 15% of each other.

Covariates {#Sec7}
----------

Severity of illness was gauged using the Sequential Organ Failure Assessment (SOFA) score, which was recorded in the intensive care unit once a day (see also Table S1 in the Electronic supplementary material, ESM, for a description of the covariates). Shock was determined as a mean arterial pressure of ≤ 60 mmHg or the infusion of at least one inotropic or vasopressive agent. Systemic inflammatory response syndrome (SIRS) was defined according to the definition of the American College of Chest Physicians (ACCP) and the Society of Critical Care Medicine Consensus Conference (SCCM) \[[@CR24]\]. Diarrhoea and ileus were documented, as well as liver injury. Daily fluid balance and body weight were recorded. Drugs influencing the pharmacokinetics of tacrolimus were recorded, including drugs that potentially increase the blood concentration of tacrolimus by inhibiting or through substrate competition for CYP3A4/5 enzymes and the ATP-binding cassette subfamily B member 1 (ABCB1) transporter, as well as drugs that potentially decrease the blood concentration of tacrolimus by inducing CYP3A4/5 enzymes or the ABCB1 transporter \[[@CR20], [@CR25]\].

Nephrotoxicity {#Sec8}
--------------

Renal function was evaluated during the first 6 days as long as the patient was admitted to the intensive care, and at 1 month after transplantation in the outpatient department (see also Table S1 in the ESM). Renal clearance was measured by analysing the creatinine concentration in 24-h urine. The occurrence of AKI and augmented renal clearance (ARC) as well as the use of continuous venovenous hemofiltration (CVVH) were monitored.

Population Pharmacokinetic Analysis {#Sec9}
-----------------------------------

The nonlinear mixed effects modelling software tool NONMEM (version 7.3.0) was used to model tacrolimus pharmacokinetics. The program Piraña (version 2.9.4) was used as an interface for NONMEM, and R for Windows (version 3.3.1) was employed to analyse the results.

The area under the concentration--time curve (AUC, in ng·h/mL) was computed using the following equation (Eq. [1](#Equ1){ref-type=""}):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{AUC}} = {\text{F}}\; \times \;{\text{AMT/CL}}$$\end{document}$$where F is the relative bioavailability, AMT is the amount of drug (in µg) and CL is the clearance (in L/h).

Population Pharmacokinetic Modelling {#Sec10}
------------------------------------

A two-compartment linear model with first-order oral absorption was used. On some occasions, the first observation within 30 min after dosing was the maximum concentration in the dose interval, indicating extremely rapid absorption. For those occasions, to reduce the complexity of the absorption model, dosing was treated as zero-order oral absorption with the duration of absorption equal to the time interval between dosing and the first observation (Fig. [1](#Fig1){ref-type="fig"}). The structural model included the following parameters: CL/F (apparent clearance), Q/F (intercompartmental clearance), V1/F (volume of distribution of the central compartment), V2/F (volume of distribution of the peripheral compartment) and*k*~a~ (absorption rate constant). IIV and IOV were described assuming a log normal distribution with the following equation (Eq. [2](#Equ2){ref-type=""}):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$P_{kjm} = \theta_{k} \times {\text{e}}^{{\left( {\eta_{kj} + \kappa_{km} } \right)}}$$\end{document}$$where *P*~*kjm*~ is the estimate for parameter *k* for the *j*th individual at occasion*m*, *θ*~*k*~ is the population value for the *k*th pharmacokinetic parameter, *η*~*kj*~ represents the IIV, which is assumed to have a normal distribution with a mean of 0 and a standard deviation of *ωk*, and *κ*~*km*~ represents the IOV, which is assumed to have a mean of 0 and a standard deviation of *πk*. Although the absolute bioavailability was not identifiable, the variability in the relative bioavailability was estimated similarly with *θ*~*k*~ fixed at 1.Fig. 1Schematic representation of the population pharmacokinetic whole-blood concentration (WBC) model for tacrolimus. The absorption phase is described by a rate constant (*k*~12~). The oral dose was treated as IV administration on some occasions. The central compartment of volume V~1~/F is in rapid equilibrium with the peripheral compartment of volume V~2~/F. Drug transfer between this peripheral compartment and the central compartment is described with the intercompartmental clearance parameter Q/F using the following equations:*k*~23 ~= Q/V~1~ and*k*~32~ = Q/V~2~. The volumes of distribution for tacrolimus can be estimated from this model. CL/F is the clearance of tacrolimus

The residual error was assumed to be proportional to the predicted concentration (Eq. [3](#Equ3){ref-type=""}):$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
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                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$C_{ij} = {\text{Cpred}}_{ij} \left( {1 + e_{ij} } \right)$$\end{document}$$where *C*~*ij*~ is the *i*th observation for the *j*th individual, Cpred~*ij*~ is the tacrolimus concentration predicted by the model, and *e*~*ij*~ is the difference between *C*~*ij*~ and Cpred~*ij*~.

The modelling process was performed using the stochastic approximation expectation maximisation (SAEM) estimation method with interaction. The likelihood was subsequently established using the Monte Carlo importance sampling EM assisted by mode a posteriori (IMPMAP) estimation method. Parameter precision was estimated using the SIR (sampling importance resampling) procedure \[[@CR26]\]. Concentrations below the lower limit of quantification (LLOQ) were discarded (3.9%; 46 values out of 1180). Model evaluation was performed by several statistical (e.g. objective function, parameter precision) and graphical (goodness-of-fit plot) methods.

Statistical Analyses {#Sec11}
--------------------

Variables are presented below as the median (with the first and third quartiles (Q1;Q3)), range or number (proportion) where appropriate.

Results {#Sec12}
=======

Patient Characteristics {#Sec13}
-----------------------

Thirty patients were included (see Table [1](#Tab1){ref-type="table"} for their characteristics, as well as Tables S1 and S2 in the ESM for more details and for definitions of the covariates). No patient died within the timeframe of the study. No organ rejection was observed in a 1-year time period. Twenty-six patients were supported with a cardiopulmonary bypass during surgery. Furthermore, 9 patients (7 lung transplants) were supported with extended extracorporeal membrane oxygenation (ECMO) for a median duration of 4 days (Q1;Q3 2;6). The median SOFA score was 7 (Q1;Q3 4;12). The frequency of shock was 93% (28 out of 30) and that of SIRS was 100% (30 out of 30). Gut dysmotility was observed in 97% of the patients (29 out of 30), with ileus in 90% of the patients (27 out of 30) and diarrhoea in 60% of the patients (18 out of 30), respectively. Three of 10 cystic fibrosis patients showed diarrhoea from days 2 and 3 on. All CF patients had exocrine pancreatic insufficiency. Pancreas enzymes were substitued when enteral feeding was implemented. Potential drug--drug interactions were observed in all patients. The number of drugs that potentially increased tacrolimus concentrations ranged from 0 to 6. The number of drugs that potentially decreased tacrolimus concentrations ranged from 0 to 2. Median baseline creatinine was 66 µmol/L (Q1;Q3 53;98). Median baseline creatinine clearance was 85 ml/min 1.73 m^2^ (Q1;Q3 73;116). Augmented renal clearance was seen in 7 out of 30 patients (23%), with a median duration of 1 day (Q1;Q3 1;2). AKI was observed in 47% of the patients (14 out of 30). The frequency of patients with AKI who showed recovery of creatinine clearance at 1 month was 64% (9 out of 14).Table 1Patient characteristics (n = 30)Variable*N* (%) Median (Q1; Q3)Male15 (50%)--Age (year)--43 (34;60)Bodyweight (kg)73.5 (61;86)Length (cm)173.5 (169;176)Reason for transplantation Heart (*N* = 10)  Ischaemic CMP5 (16.7%)--  Non-ischaemic CMP5 (16.7%)-- Lung (*N* = 20)  Cystic fibrosis10 (33.3%)--  COPD4 (13.3%)--  ILD6 (20%)--  Double lung transplantation18 (90%)--Parameters SOFA score7 (4;12) SIRS at least once between days 1 and 630 (100%) SIRS duration (days)4.5 (3;6) Shock at least once between days 1 and 628 (93.3%) Shock duration (days)2 (1;3) Liver dysfunction at least once between days 1 and 614 (47%) Gut dysmotility frequency29 (96.7%) Ileus at least once between days 1 and 627 (90%) Ileus duration2 (2; 3) Diarrhea at least once between days 1 and 618 (60%) Diarrhea duration1 (0;2) Fluid balance (L/day)  Day 11.5 (0.2;3)  Day 21.2 (0.4;2.2)  Day 30.5 (− 0.2;1.5)  Day 40.4 (− 0.8;0.9)  Day 5− 0.3 (− 1.0;1.1)  Day 6− 0.2 (− 1.4;0.0) Change in bodyweight from baseline (kg)  Day 11.5 (0;6)  Day 26.5 (0.8;11)  Day 38 (0;14)  Day 410 (0.5;14.5)  Day 57 (− 1;14.5)  Day 65 (− 0.8;18.5) Postoperative ECMO frequency8 (27%) Postoperative ECMO duration (days)4 (2;6)Tacrolimus Tacrolimus C12 h (ng/ml) (min--max)9.5 (0.5--38.7) *C*~max~ (ng/ml)18.5 (2.1--74.7) *T*~max~ (h)1.6 (0.4--8.0) AUC (ng·h/mL)151.2 (31.2--2525) *T*~1/2~ (h)9.4 (6.0--31.4) Patients with at least one drug that increased tacrolimus levels between days 1 and 630 (100%) Number of drugs that increased the tacrolimus concentration (min--max)0--6 Patients with at least one drug that decreased tacrolimus levels between days 1 and 630 (100%) Number of drugs that decreased the tacrolimus concentration (min--max)0--2Renal function Baseline creatinine (µmol/L)66 (53;98) Baseline creatinine clearance (ml/min/1.73 m^2^)85 (73;116) ARC at least once between days 1 and 67 (23.3%) ARC duration (days) (min--max)1 (1-6) AKI at least once between days 1 and 614 (47%) AKI recovery at 1 month9^a^ (64%)*SOFA* sequential organ failure assessment,*SIRS* systemic inflammatory response syndrome, *ECMO* extracorporeal membrane oxygenator, *C12* *h* concentration 12 h after administration, *C*~*max*~ maximum C12 h, *T*~*max*~ time to maximum concentration, *AUC* area under the concentration--time curve,*T*~*1/2*~ terminal half-life, *ARC* augmented renal clearance, *AKI* acute kidney injury, *CMP*  cardiomyopathy, *COPD* chronic obstructive pulmonary disease, *ILD* interstitial lung disease ^*a*^Of 14 patients

Pharmacokinetic Profiles {#Sec14}
------------------------

The total number of whole-blood C12 h profiles was 119, with a median of 5 profiles per patient (range 1--6). Characteristic features of the whole-blood tacrolimus concentrations together with the dosages are illustrated in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Three illustrative individual whole-blood concentration (WBC) profiles showing the administered tacrolimus dose and the individual predicted lines. The therapeutic range for tacrolimus C12 h is indicated by*grey bars*. UTN7: This patient presented C12 h values below the therapeutic range, despite increasing the dosage. The patient was a heart transplant recipient with shock and circulatory support for 4 days. Gut dysmotility was observed for 3 days. UTN13: In this patient, absorption was rapid and complete, with a short*T*~max~ and a high*C*~max~. This patient was an uncomplicated non-CF lung transplantation patient. Cardiopulmonary bypass was used during surgery. Hyperdynamic circulation in combination with augmented renal clearance existed for 3 days. Diarrhoea was observed on days 4 and 5. UTN14: This patient was a heart transplant recipient and had severe bleeding during surgery, for which two red blood cell units were administered on day 1. For 5 days, he was supported with ECMO, vasopressors and inotropes because he was in shock. Fluid balance ranged from 1 to 4 litres. No gut dysmotility occurred. Very low C12 h values were measured during days 1 and 2, which would support the idea of low absorption or distribution into the red blood cells. High clearance was observed from day 3 to day 6. High doses were needed to achieve a therapeutic C12 h. *CF* cystic fibrosis, *C12* concentration at 12 h, *C*~*max*~ maximum C12 concentration, *T*~*max*~ time to reach C~max~

Observed Pharmacokinetics {#Sec15}
-------------------------

The median C12 h was 9.5 ng/ml (range 0.5--38.7). Most of the whole-blood concentrations, 69.4%, were outside the target range (9--15 ng/ml). Subtherapeutic concentrations were observed in 51% and supratherapeutic concentrations were observed in 19% of the patients. The median of the maximum concentration (*C*~max~) was 18.5 ng/ml (range 2.1--74.7). The median of the time to maximum concentration (*T*~max~) was 1.6 h (range 0.4--8).

Pharmacokinetic Model for Tacrolimus {#Sec16}
------------------------------------

A two-compartment model with first-order absorption or zero-order absorption in a few cases best fitted the data (for a schematic illustration of the pharmacokinetic model, see Fig. [1](#Fig1){ref-type="fig"}). The parameter precision was acceptable for all relevant parameters, as indicated by the low 95% confidence intervals (CIs) for the parameter estimates, indicating that all of the parameters could be reliably estimated (see Table [2](#Tab2){ref-type="table"}). Goodness-of-fit plots of whole-blood tacrolimus concentrations (Fig. [3](#Fig3){ref-type="fig"}) showed that the data were widely dispersed around the unity line when the model with the population parameter estimates (upper right panel) was applied.Table 2Final population pharmacokinetic parameters with 95% confidence intervals, as obtained using SIRPharmacokinetic parameterEstimate (95% CI)Interpatient variability  % (95% CI)Inter-occasion variability  % (95% CI)CL/F (L/h)19.6 (16.2--22.9)34.6 (24.2--48.6)29.5 (20.7--38.9)V~1~/F (L)231 (199--267)n.e.35.1 (27.0--48.0)*k*~a~ (1/h)0.579 (0.456--0.778)n.e.98.3 (81.1--121)Q/F (L/h)58.2 (49.7--69.3)n.e.n.e.V~2~/F (L)521 (441--634)n.e.n.e.FFixed at 1n.e.55.0 (48.5--64.4)Residual unexplained variability (%)14.0 (13.3--14.6)*SIR* sampling importance resampling,*n.e.* not estimated, *CI* confidence interval, *k*~*a*~ absorption rate constant, *CL/F*apparent clearance, *V1/F* central compartment volume of distribution, *V2/F* peripheral compartment volume of distribution,  *Q/F* intercompartmental clearance, *F* bioavailabilityFig. 3Goodness-of-fit plots

The IOV in relative bioavailability was estimated at 55.0% (95% CI 48.5--64.4). The IOV in apparent clearance was 29.5% (95% CI 20.7--38.9), and the IOV in the apparent distribution volume was 35.1% (95% CI 27.0--48.0). Only the IIV of CL/F could be estimated; the estimation of all other IIV elements yielded estimates close to 0 and/or unsuccessful runs, most likely due to the fact that variability was dominated by the corresponding IOV. No further formal covariate analysis was conducted. Time-independent covariates (such as genotype or gender) are by definition not predictive for the observed IOV. The time-dependent covariates available (such as gut dysmotility, shock and corticosteroid use) changed much more slowly over time than the observed IOV. Furthermore, the magnitude of the change in each of these covariates was much lower than the IOV. Therefore, these covariates were unable to explain the extreme IOV observed. The median AUC was 151.2 ng·h/mL (range 31.2--2525). The median terminal*T*~1/2~ was 9.4 h (range 6.0--31.4).

Discussion {#Sec17}
==========

In this pharmacokinetic analysis involving 30 thoracic organ recipients, we showed that the bioavailability of tacrolimus displays a large IOV in the first week after transplantation. Other pharmacokinetic parameters also showed large IOVs. These high variabilities hamper attempts to predict appropriate next-dose tacrolimus concentrations based upon previous concentrations. In other words, pharmacokinetic-guided dosing seems to be of limited added value in clinically unstable patients. Nevertheless, daily therapeutic drug monitoring remains worthwhile for the prevention of toxicity, since subsequent doses will be omitted in the presence of high concentrations. In order to optimise tacrolimus therapy, it may be useful to circumvent bioavailability issues by administering it intravenously during clinical instability.

In general, tacrolimus is orally dosed after thoracic organ transplantation even when gut dysmotility ensues, because tacrolimus has known nephrotoxicity and intravenous administration may cause additional nephrotoxicity due to the use of the solvent HCO-60 \[[@CR1], [@CR2]\]. When the oral route is not feasible, sublingual administration has been recommended over intravenous administration by some authors, though this is not sufficiently substantiated yet and is therefore not common practice \[[@CR27]\].

Very few studies have analysed the pharmacokinetics of oral tacrolimus in clinically unstable transplantation patients \[[@CR17], [@CR18], [@CR28]\]. Unfortunately, none of these studies reported severity of illness, shock or organ failure, hampering any comparison of the outcomes. Our cohort of thoracic organ transplant patients showed high SOFA scores, and many had shock in the first week, corresponding to major physiological instability. We observed a high inter-occasion (i.e. between-dose) variability in bioavailability independent of the dose, indicating unpredictable uptake of tacrolimus, which is probably related to this clinical instability. This contrasts with kidney transplant recipients early after transplantation, in whom bioavailability was observed to be dose dependent and had a much smaller IOV of only 23--28% \[[@CR29], [@CR30]\]. Renal transplant patients are often clinically stable, and many do not need ICU support in the days after transplantation. Tacrolimus target concentrations are frequently reached in renal recipients within 3 days, which is different from our cohort of heart and lung recipients \[[@CR31]\]. Despite the large differences in absorption variability, the observed clearance as well as the variability in clearance was in accordance with earlier reports \[[@CR14], [@CR16], [@CR28], [@CR30], [@CR32]\]. The distribution volumes in our cohort were only slightly higher than those in another study conducted 1 week after lung transplantation, and both studies had similar distribution volume IOVs \[[@CR14]\].

The high IOV observed for tacrolimus pharmacokinetics in our study population may be explained by a range of factors, all of which are associated with clinical instability. First, delayed absorption as well as very early absorption were observed in our data, which may be partly explained by a high incidence of gut dysmotility in all of our patients with and without CF. Ileus delays tacrolimus transport to the duodenum, where it is mainly absorbed \[[@CR33]\]. On the other hand, the prompt absorption of tacrolimus with a sudden peak in blood concentration may be due to a short transit time to the duodenum, which may be caused by a hyperdynamic state and (e.g. mycophenolate-associated) diarrhoea \[[@CR33]--[@CR35]\]. Furthermore, increased gut perfusion may increase absorption by augmented enteric drug extraction due to a large difference in intracellular and blood concentrations, and diarrhoea may increase absorption by shortening the transit time and maximising luminal degradation and dissolution of tacrolimus \[[@CR36]\]. Moreover, diarrhoea, shock and inflammation may result in decreased ABCB1 and CYP3A4/5 expression \[[@CR37]--[@CR39]\]. These phenomena could all increase tacrolimus transport and also shorten the transit time across the gut wall into the blood compartment, giving rise to sudden higher peak concentrations \[[@CR33]\].

Second, the distribution of tacrolimus may fluctuate due to changes in diffusion into erythrocytes and reduced binding to (lipo)proteins caused by red blood cell transfusion, bleeding, dilution caused by fluid resuscitation, capillary leakage and the use of an extracorporeal circuit \[[@CR40]\]. Anaemia and hypoalbuminaemia were observed in all the patients (see Table S1 in the ESM), which may lead to higher unbound tacrolimus concentrations with lower whole-blood levels at equivalent doses \[[@CR28], [@CR41], [@CR42]\]. The application of an extracorporeal circuit, such as a cardiopulmonary bypass, ECMO or continuous renal replacement therapy, may significantly alter the disposition of tacrolimus because of adsorption to the bypass equipment, acute haemodilution, hypoalbuminaemia and hypothermia \[[@CR43], [@CR44]\]. Third, drug--drug interactions influence tacrolimus bioavailability. We observed drug--drug interactions in all patients. For example, high-dose corticosteroids induce CYP3A enzymes and ABCB1. Therefore, tapering corticosteroids decreases the activities of both and may greatly increase tacrolimus bioavailability, especially in CYP3A5 nonexpressers \[[@CR37], [@CR45], [@CR46]\]. Last, changes in the clearance of tacrolimus might contribute to fluctuations in whole-blood concentrations. Shock and inflammation strongly influence organ function and subsequently the metabolisation rate of the liver \[[@CR25], [@CR47], [@CR48]\].

All of these variations in the covariates of tacrolimus pharmacokinetics give rise to high fluctuations in whole-blood tacrolimus concentrations and hence a persistently high IOV in the first week after thoracic organ transplantation \[[@CR20]\]. The IOV in bioavailability far exceeded other sources of variability. No covariate relationships were identified, as no covariate (time dependent or time independent) was identified that could explain the large variability in bioavailability. Yet, fluctuations in tacrolimus concentrations are a known significant risk factor for rejection, toxicity, and outcome deterioration in heart and lung transplants \[[@CR3], [@CR4], [@CR7]--[@CR10]\].

Future Perspectives {#Sec18}
-------------------

Circumventing the high variability in bioavailability by administering tacrolimus intravenously may improve tacrolimus dosing despite the higher costs and the risk of additional nephrotoxicity from the solvent HCO-60 \[[@CR2], [@CR20], [@CR49]\]. This will result in a decrease in tacrolimus concentration fluctuations and a subsequent decrease in the incidence of supratherapeutic C12 h. Therapeutic drug monitoring of C12 h on a daily basis is mandatory in clinically unstable patients to improve dosing \[[@CR17], [@CR20]\]. However, we showed that targeting the therapeutic range is impossible due to a high IOV. The therapeutic range of 10--15 ng/ml, which is often used, is difficult to attain in clinically unstable patients \[[@CR22]\]. Our findings support a more cautious approach. Targeting below the upper level of the therapeutic range (e.g. 15 ng/ml) at day 5 after transplantation and not increasing the dose when low concentrations exist until clinical stability is established could help to prevent toxicity. Tacrolimus should be temporarily stopped when supratherapeutic concentrations arise. However, even lower therapeutic ranges might be advocated, as concentrations of \> 10 ng/ml have already been associated with AKI \[[@CR50]\]. It has even been suggested that an initial concentration of less than 4 ng/ml should be targeted, though early rejection may then arise, jeopardising the outcome \[[@CR51]\]. To maintain adequate immunosuppression, corticosteroid dosage should not be tapered during clinical instability. In addition, accurate dosing of cell cycle inhibitors (e.g. MMF) and interleukin receptor blockers (e.g. basiliximab) is advocated to diminish the risk of rejection \[[@CR11], [@CR51]--[@CR54]\]. In heart transplants, initiation of tacrolimus may even be postponed for 1 week when an interleukin receptor blocker is administered \[[@CR55]\]. However, postponing tacrolimus may have very negative consequences for lung transplantation patients due to acute rejection \[[@CR56]\].

Study Limitations and Strengths {#Sec19}
-------------------------------

Strong features of this study are the use of full 12-h pharmacokinetic profiles on a daily basis and the application of high-performance liquid chromatography with tandem mass spectrometry (HPLC--MS/MS) for analyses of blood concentrations. HPLC--MS/MS is a very accurate analytical method compared to immunoassays. However, some limitations of this study should also be noted. Overall, the sample size was relatively small, although these patients were sampled throughout during their ICU admission. Also, it is known that food impacts the absorption of tacrolimus \[[@CR57]\], and enteral feeding was employed continuously in this study (it was not paused in any patient). We assume that the presence of ileus or diarrhoea will have had a major impact on absorption. The aim of this study was to examine tacrolimus pharmacokinetics in clinically unstable patients. These data are a good reflection of clinical practice, since large variations in whole-blood concentrations are frequently observed in the early phase after heart and lung transplantation.

Conclusions {#Sec20}
===========

Variability in whole-blood tacrolimus concentrations was excessive in clinically unstable thoracic organ transplantation patients. The pharmacokinetics of tacrolimus showed high IOVs. in particular, the IOV in relative bioavailability was excessive and was superimposed upon the variability in apparent distribution and apparent clearance. This makes pharmacokinetic-guided dosing to a preset narrow therapeutic range an impossible task in these patients. We suggest administering tacrolimus intravenously and aiming below the upper therapeutic range during the first few days after transplantation.
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